Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Blood (2021) 137 (10): 1377–1391.

https://doi.org/10.1182/blood.2020007897

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting the p-D-C: easy as C-D-1-2-3?

Naveen Pemmaraju

Blood (2021) 137 (10): 1277–1278.

https://doi.org/10.1182/blood.2020008745

Published: 2021

Journal Articles

CD123 + CD4 + CD56 + neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia?

Wei Wang, Beenu Thakral

Blood (2020) 136 (13): 1565.

https://doi.org/10.1182/blood.2020007274

Published: 2020

Journal Articles

Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation

Hui Liu, Shimin Hu

Blood (2020) 135 (17): 1506.

https://doi.org/10.1182/blood.2020005039

Published: 2020

Journal Articles

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

Jason G Underwood, PhD BA, Jenny L. Smith, MSc, MD, Lindsey F. Call, B.A., Elizabeth Tseng, PhD, Tiffany A. Hylkema, BS, Rhonda E. Ries, MA, Amanda R. Leonti, MS, Jason E. Farrar, MD, Timothy Junius Triche, Jr., PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 4658.

https://doi.org/10.1182/blood-2019-131508

Published: 2019

Journal Articles

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Vinitha Mary Kuruvilla, MSc, Rebecca McCarthy, Qi Zhang, PhD, Callum M. Sloss, PhD, Patrick A. Zweidler-McKay, MD PhD, Angela Romanelli, PhD, Sharlene Adams, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1375.

https://doi.org/10.1182/blood-2019-124963

Published: 2019

Journal Articles

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Aishwarya Krishnan, Maria Pagane, Mikhail Roshal, MD PhD, Erin McGovern, BA, Zoe Stone-Molloy, Janice Chen, PhD, Christopher Brooks, PhD, Ross L. Levine, MD, Raajit K. Rampal, MD PhD

Blood (2019) 134 (Supplement_1): 2967.

https://doi.org/10.1182/blood-2019-129397

Published: 2019

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Srdan Verstovsek, MD PhD, Nitin Jain, MD, Madeline Duvic, MD, Phyu Aung, MD, C. Cameron Yin, MD PhD, Sergej Konoplev, Keyur P. Patel, MBBS, PhD, Sherry A. Pierce, BSN, BA, Hannah Beird, PhD, Muzaffar H. Qazilbash, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2723.

https://doi.org/10.1182/blood-2019-132185

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact

Anna Stengel, PhD, Wencke Walter, PhD, Constance Baer, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2019) 134 (Supplement_1): 1234.

https://doi.org/10.1182/blood-2019-125645

Published: 2019

Journal Articles

Combination of Venetoclax and Hypomethylating Agents in Myeloid Malignancies in Patients Unfit for Intensive Chemotherapy - Real World Data from a Tertiary Care Centre in India. Is It Time to Bid Adieu to 3+7?

Sumeet Prakash Mirgh, MBBS, MDDM, Jyotsna Kapoor, MSc, Shinto Francis Thekuddan, MD DM, Vishvdeep Khushoo, MBBS, MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5149.

https://doi.org/10.1182/blood-2019-131746

Published: 2019

Journal Articles

Analysis of Elderly Patients (≥70 years old) with Acute Leukemia in the Era of Targeted Therapy

Alon Rozental, MD, Shai Shimony, MD, Pia Raanani, MD, Ofir Wolach, MD

Blood (2019) 134 (Supplement_1): 5100.

https://doi.org/10.1182/blood-2019-121904

Published: 2019

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Paul G. Richardson, MD, Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey A. Zonder, Thomas G. Martin, III, MD, Janice Chen, PhD, Christopher Brooks, PhD, Peter McDonald, Nicole Rupprecht, Halyna Wysowskyj, Dharminder Chauhan, PhD, Arghya Ray, PhD, Kenneth C. Anderson, MD, Claudia E. Paba-Prada, MD

Blood (2019) 134 (Supplement_1): 3145.

https://doi.org/10.1182/blood-2019-130410

Published: 2019

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark

Justin Taylor, Michael Haddadin, Vivek A. Upadhyay, Erwin Grussie, Neha Mehta-Shah, Andrew M. Brunner, Abner Louissaint, Jr, Scott B. Lovitch, Ahmet Dogan, Amir T. Fathi, Richard M. Stone, Martin S. Tallman, Raajit K. Rampal, Donna S. Neuberg, Kristen E. Stevenson, Steven M. Horwitz, Andrew A. Lane

Blood (2019) 134 (8): 678–687.

https://doi.org/10.1182/blood.2019001144

Published: 2019

Includes: Supplemental data

Journal Articles

Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Joseph David Khoury, MD, Susan M. O'Brien, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Phyu Aung, MD, C. Cameron Yin, MD PhD, Sergej Naumovich Konoplev, MD PhD, Keyur Patel, MD PhD, Sherry A. Pierce, BSN, BA, Lingsha Zhou, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 3980.

https://doi.org/10.1182/blood-2018-99-119888

Published: 2018

Journal Articles

Transcriptomic Microarray Profile Analysis between Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and TET2 -Mutated Acute Myeloid Leukemia (AML)

Hannah Beird, PhD, Maliha Khan, Feng Wang, PhD, Mansour Alfayez, MD, Tianyu Cai, PhD, Li Zhao, PhD, Andy Futreal, PhD, Marina Y. Konopleva, MD PhD, Naveen Pemmaraju, MD

Blood (2018) 132 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2018-99-118674

Published: 2018

Journal Articles

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Naval G. Daver, MD, Harry P. Erba, MDPhD, Nikolaos Papadantonakis, MDPhDMSc, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Marina Y. Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2018) 132 (Supplement 1): 27.

https://doi.org/10.1182/blood-2018-99-112955

Published: 2018

Journal Articles

Developmental Ontogeny of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Revealed By Recurrent High Burden Clonal Hematopoiesis, Including in "Skin-Only" Disease

Gabriel K Griffin, MD, Katsuhiro Togami, MD PhD, Elizabeth A Morgan, MD, Andrew A. Lane, MD PhD

Blood (2018) 132 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2018-99-119945

Published: 2018

NARROW

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Targeting the p-D-C: easy as C-D-1-2-3?

CD123 + CD4 + CD56 + neoplasm: blastic plasmacytoid dendritic cell neoplasm or acute myeloid leukemia?

Acute leukemic variant of blastic plasmacytoid dendritic cell neoplasm at initial presentation

Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics

IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo , Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)

Evaluation of Tagraxofusp (SL-401) Alone and in Combination with Ruxolitinib for the Treatment of Myeloproliferative Neoplasms

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Comprehensive Analysis of 22 Cases with Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Mutations in DNA Repair Genes and Two Distinct Subgroups Defined By Differential Gene Expression with Prognostic Impact

Combination of Venetoclax and Hypomethylating Agents in Myeloid Malignancies in Patients Unfit for Intensive Chemotherapy - Real World Data from a Tertiary Care Centre in India. Is It Time to Bid Adieu to 3+7?

Analysis of Elderly Patients (≥70 years old) with Acute Leukemia in the Era of Targeted Therapy

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark

Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation

Transcriptomic Microarray Profile Analysis between Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and TET2 -Mutated Acute Myeloid Leukemia (AML)

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

Developmental Ontogeny of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Revealed By Recurrent High Burden Clonal Hematopoiesis, Including in "Skin-Only" Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only